

RATIONALE CHOICE OF FLUOROQUINOLONES IN TREATMENT OF PATIENTS WITH TUBERCULOSIS AND COMPARATIVE ANALYSIS OF THEIR TOLERABILITY IN LONG-TERM APPLICATION

S. A. Cherenko, E. V. Ivankova

Summary

On the basis of literature data about activity of fluoroquinolones against *Mycobacterium tuberculosis*, pharmacokinetics, side effects, cost effectiveness in Ukraine, and own data of tolerability of fluoroquinolones in 235 patients with multidrug resistant tuberculosis, we developed the rationale for the choice of fluoroquinolones in treatment of patients with tuberculosis. Ofloxacin and lomefloxacin are the beneficial drugs due to their activity against MBT, pharmacokinetics, safety profile and low cost in Ukraine. Lomefloxacin has better pharmacokinetic and safety profile (can be used once daily in dose 0,4 g in continuation phase and better penetrate in macrophages). Levofloxacin differs from fluoroquinolones of 2-nd generation by higher activity against MBT, good safety profile, but it costs much more in Ukraine, limiting its long-term application. We think that levofloxacin and moxifloxacin are the drugs of the choice for treatment of severe forms of tuberculosis, which are resistant to the therapy with fluoroquinolones of 2-nd generation.